Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders

被引:5
作者
Valdivia-Tangarife, Edgar R. [1 ]
Gamez-Nava, Jorge, I [1 ,2 ]
Cortes-Enriquez, Fernando [3 ]
Mireles-Ramirez, Mario A. [4 ]
Gonzalez-Lopez, Laura [1 ,2 ]
Saldana-Cruz, Ana M. [5 ]
Angel Macias-Islas, Miguel [6 ]
机构
[1] Univ Guadalajara, Ctr Univ Ciencias Salud CUCS, Farmacol, Guadalajara 44340, Jalisco, Mexico
[2] Univ Guadalajara, CUCS, Salud Publ, Guadalajara 44340, Jalisco, Mexico
[3] Inst Mexicano Seguro Social, Dept Neurol, Hosp Gen Reg 45, Guadalajara, Jalisco, Mexico
[4] Inst Mexican Seguro Social, Ctr Med Nacl Occidente, Unidad Alta Especialidad Med, Dept Neurol, Guadalajara, Jalisco, Mexico
[5] Univ Guadalajara, Inst Terapeut Expt & Clin, Dept Fisiol, CUSC, Cusc, Jalisco, Mexico
[6] Univ Guadalajara, Dept Neurociencias, Guadalajara 44340, Jalisco, Mexico
关键词
Risk Factors; Permanent Disability; Permanent visual disability; Permanent motor disability; Neuromielitis Optica Spectrum Disorders; PROGRESSION; ONSET;
D O I
10.1016/j.msard.2022.104114
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system. In NMOSD, a relapse results in increased disability. Objective: To assess risk factors associated with permanent disability (PD) in patients with neuromyelitis optica spectrum disorders (NMOSD). Methods: We evaluated 34 cases (who developed permanent disability) and 33 controls. The assessment included the following variables: sociodemographic data and characteristics of the disease. Logistic regression analysis was performed to adjust variables associated with PD. Results: fifty-one percent developed PD during follow-up; 15 (22%) developed permanent visual disability, 13 (19%) developed permanent motor disability and 6 (9%) were restricted to wheelchair. Factors associated with PD in the crude analysis were: age at onset >= 50 years (OR 3.95, 95% IC 1.12-13.94, p= 0.032), time from onset to diagnosis >= 12 months (OR 3.30, 95% IC 1.13-9.64, p= 0.029), time from onset to treatment >= 60 months (OR 4.16, 95% IC 1.03-16.85, p= 0.045), EDSS >= 4.0 at the first appointment (OR 3.21, 95% IC 1.18-8.76, p= 0.022) and severe relapses during disease evolution (OR 5.72, 95% IC 1.98-16.57, p= 0.001). Factors associated with PD in the adjusted analysis were: age at onset >= 50 years (OR 5.82, 95% IC 1.30-26.05, p= 0.021), time from onset to diagnosis >= 12 months (OR 5.43, 95% IC 1.47-20.08, p= 0.011) and severe relapses during disease evolution (OR 6.65, 95% IC 1.98-22.31, p= 0.002). Conclusion: Half of patients with NMOSD may develop PD during disease evolution. Age of onset >= 50 years, delay to diagnosis >= 12 months and initial EDSS >= 4.0 constitute the strongest risk factors for PD.
引用
收藏
页数:5
相关论文
共 30 条
  • [1] A prospective study on the prognosis of multiple sclerosis
    M.P. Amato
    G. Ponziani
    [J]. Neurological Sciences, 2000, 21 (Suppl 2) : S831 - S838
  • [2] Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
    Amato, Maria Pia
    Fonderico, Mattia
    Portaccio, Emilio
    Pasto, Luisa
    Razzolini, Lorenzo
    Prestipino, Elio
    Bellinvia, Angelo
    Tudisco, Laura
    Fratangelo, Roberto
    Comi, Giancarlo
    Patti, Francesco
    De Luca, Giovanna
    Morra, Vincenzo Brescia
    Cocco, Eleonora
    Pozzilli, Carlo
    Sola, Patrizia
    Bergamaschi, Roberto
    Salemi, Giuseppe
    Inglese, Matilde
    Millefiorini, Enrico
    Galgani, Simonetta
    Zaffaroni, Mauro
    Ghezzi, Angelo
    Salvetti, Marco
    Lus, Giacomo
    Florio, Ciro
    Totaro, Rocco
    Granella, Franco
    Vianello, Marika
    Gatto, Maurizia
    Di Battista, Giancarlo
    Aguglia, Umberto
    Logullo, Francesco Ottavio
    Simone, Marta
    Lucisano, Giuseppe
    Iaffaldano, Pietro
    Trojano, Maria
    [J]. BRAIN, 2020, 143 : 3013 - 3024
  • [3] Infectious disease risk in the elderly
    Bender, BS
    [J]. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2003, 23 (01) : 57 - +
  • [4] Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort
    Carnero Contentti, Edgar
    Daccach Marques, Vanessa
    Soto de Castillo, Ibis
    Tkachuk, Veronica
    Ariel, Bustos
    Castillo, Maria C.
    Cristiano, Edgardo
    Diegues Serva, Gabriel Braga
    dos Santos, Antonio Carlos
    Finkelsteyn, Ana Mariel
    Lopez, Pablo A.
    Patrucco, Liliana
    Molina, Omaira
    Pettinicchi, Juan Pablo
    Toneguzzo, Vanesa
    Caride, Alejandro
    Rojas, Juan Ignacio
    [J]. JOURNAL OF NEUROLOGY, 2020, 267 (05) : 1260 - 1268
  • [5] Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
    Collongues, N.
    Marignier, R.
    Jacob, A.
    Leite, M. I.
    Sivas, A.
    Paul, F.
    Zephir, H.
    Akman-Demirs, G.
    Elsone, L.
    Jarius, S.
    Papeix, C.
    Mutch, K.
    Saips, S.
    Wildemann, B.
    Kitley, J.
    Karabudak, R.
    Aktas, O.
    Kuscu, D.
    Altintas, A.
    Palace, J.
    Confavreux, C.
    De Seze, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (08) : 1086 - 1094
  • [6] Characteristics of Devic's disease (neuromyelitis optica) in Mexico
    Flores Rivera, Jose
    Kurtzke, John F.
    Alatriste Booth, Vanessa J.
    Corona V., Teresa
    [J]. JOURNAL OF NEUROLOGY, 2008, 255 (05) : 710 - 715
  • [7] Late Onset of Neuromyelitis Optica Spectrum Disorders
    Fragoso, Yara Dadalti
    Ruocco, Heloisa Helena
    Dias, Ronaldo Maciel
    Cabeca, Hideraldo
    Goncalves, Ricardo
    de Carvalho Sousa, Nise A.
    Spessotto, Caroline Vieira
    Tauil, Carlos Bernardo
    Alves-Leon, Soniza Vieira
    Gomes, Sidney
    Goncalves, Marcus Vinicius M.
    Nunes Machado, Suzana C.
    Anacleto, Andrea
    Correa, Eber Castro
    Pimentel, Maria Lucia V.
    Santos, Gutemberg Augusto C.
    [J]. NEUROLOGY AND THERAPY, 2019, 8 (02) : 477 - 482
  • [8] Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan
    Houzen, Hideki
    Kondo, Kimito
    Niino, Masaaki
    Horiuchi, Kazuhiro
    Takahashi, Toshiyuki
    Nakashima, Ichiro
    Tanaka, Keiko
    [J]. NEUROLOGY, 2017, 89 (19) : 1995 - 2001
  • [9] Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
    Jarius, Sven
    Ruprecht, Klemens
    Wildemann, Brigitte
    Kuempfel, Tania
    Ringelstein, Marius
    Geis, Christian
    Kleiter, Ingo
    Kleinschnitz, Christoph
    Berthele, Achim
    Brettschneider, Johannes
    Hellwig, Kerstin
    Hemmer, Bernhard
    Linker, Ralf A.
    Lauda, Florian
    Mayer, Christoph A.
    Tumani, Hayrettin
    Melms, Arthur
    Trebst, Corinna
    Stangel, Martin
    Marziniak, Martin
    Hoffmann, Frank
    Schippling, Sven
    Faiss, Juergen H.
    Neuhaus, Oliver
    Ettrich, Barbara
    Zentner, Christian
    Guthke, Kersten
    Hofstadt-van Oy, Ulrich
    Reuss, Reinhard
    Pellkofer, Hannah
    Ziemann, Ulf
    Kern, Peter
    Wandinger, Klaus P.
    Bergh, Florian Then
    Boettcher, Tobias
    Langel, Stefan
    Liebetrau, Martin
    Rommer, Paulus S.
    Niehaus, Sabine
    Muench, Christoph
    Winkelmann, Alexander
    Zettl U, Uwe K.
    Metz, Imke
    Veauthier, Christian
    Sieb, Joern P.
    Wilke, Christian
    Hartung, Hans P.
    Aktas, Orhan
    Paul, Friedemann
    [J]. JOURNAL OF NEUROINFLAMMATION, 2012, 9
  • [10] The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives
    Jasiak-Zatonska, Michalina
    Kalinowska-Lyszczarz, Alicja
    Michalak, Slawomir
    Kozubski, Wojciech
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (03):